### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Report on age and sex for all study participants.

### **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	Methods: lines 111-238	yes
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
	No cell lines were used in this study. Methods: lines	
<b>Cell lines:</b> Provide species information, strain.	111-238	n/a
Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number,	111-238	
OR RRID		
Primary cultures: Provide species, strain, sex of	No cell lines were used in this study. Methods: lines	n/a
origin, genetic modification status.	111-238	
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	No animals were used in this study. Methods: lines	n/a
genetic modification status. Provide accession	111-238	
number in repository <b>OR</b> supplier name, catalog		
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the	No animals were used in this study. Methods: lines	n/a
field: Provide species, sex and age where	111-238	
possible		
Model organisms: Provide Accession number	No organisms were used in this study. Methods: lines	n/a
in repository (where relevant) <b>OR</b> RRID	111-238	
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	No plants were used in this study. Methods: lines 111-	n/a
number if available, and source (including location	238	
for collected wild specimens)		
Microbes: provide species and strain, unique	No microbes were used in this study. Methods: lines	n/a
accession number if available, and source	111-238	
Harris and the salt do not	Vac (indicate whose provided, costion /paragraph)	2/2
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Methods: lines 190-191; Results: lines 320-323	yes
equivalent committee(s), provide reference number for approval.		
	This was a retrospective study using archived eliminal	l voc
Provide statement confirming informed consent	This was a retrospective study using archived clinical	yes
obtained from study participants.	pathology tissue samples.	

Results: lines 205-226; Table #1 - lines 326-330; Table

#3 – 339-341; Supplemental Table #1 – lines 351-356

yes

number for the regulatory approval

#### **Design**

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration	This was not a clinical trial nor were the tissue samples	yε
number <b>OR</b> cite DOI in manuscript.	used obtained through a clinical trial.	S
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	Methods: lines 87-200	ye s
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, <b>or</b> if they were not carried out.		
Sample size determination	The number of cases was determined by available archived tissue blocks. Methods: lines 111-238	n/ a
Randomisation	This was a retrospective study.	ye
Blinding	This was a retrospective study.	ye
Inclusion/exclusion criteria	All available tissue blocks were included.	yε
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Methods: Lines 182-183	ye s
Define whether data describe technical or biological replicates	Data describe technical replicates.	ye s
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods: lines 186-187 This study conformed to the provisions of the Declaration of Helsinki (as revised in 2013), available at <a href="https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2013-JAMA.pdf">https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2013-JAMA.pdf</a> . Appears in Methods Section	y€ s
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No animals were used in this study. Methods: lines 111-238	n/ a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	IRB approval was obtained but no special permits were required for the protocol and study design. Methods: lines 111-238	n, a
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,	Study is not subject to dual use research of concern.	

# <u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	No data points were excluded in the analyses. Methods: lines 111-238	n/ a

Statistics	Yes (indicate where provided: section/paragraph)	n/a	
Describe statistical tests used and justify choice of	Methods: lines 194-200	ye	
tests.		S	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	None. Methods: lines 111-238	n/
including protocols for access or restriction on		а
access.		
If data are publicly available, provide accession	Data are provided in paper.	ye
number in repository or DOI or URL.		S
If publicly available data are reused, provide	Data were not reused from publicly available database.	ye
accession number in repository or DOI or URL, where		S
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	No code or software was generated in this study.	ye
If code is publicly available, provide accession	No code or software was generated in this study.	ye
number in repository, or DOI or URL.		S

# Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of	Footnote 1	ye
discipline-specific guidelines, established and		S
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	ye
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	S
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: http://dx.doi.org/10.21037/gist-20-2